Medication | TCA | SSRI | SNRI | NRI | Low-Dose SARI | NaSSA | rMAO-A | Hypericum | Placebo |
---|---|---|---|---|---|---|---|---|---|
TCA | |||||||||
OR (95% CI)^{a} | 0.95 (0.84–1.08) | 0.83 (0.37–1.89) | na | 1.43 (0.60–3.42) | 3.83 (1.67–8.75) | 1.65 (1.16–2.34) | 0.87 (0.54–1.41) | 1.67 (1.24–2.25) | |
No. of studies; I^{2}, %; P value^{b} | 18; 0; .45; | 2; 55; 0.14 | na | 2; 79; .03 | 1 | 3; 0; .79; | 2; 24; 0.25; | 8; 25; .23; | |
OR (95% CI)^{c} | 1.04 (0.88–1.21) | 1.00 (0.71–1.40) | 1.23 (0.73–2.14) | 0.97 (0.65–1.47) | 1.55 (1.11–2.18) | 1.65 (1.10–2.45) | 0.86 (0.67–1.10) | 1.75 (1.42–2.15) | |
SSRI | |||||||||
OR (95% CI)^{a} | 1.05 (0.93–1.19) | 0.92 (0.67–1.25) | 1.18 (0.85–1.65) | na | 1.05 (0.54–2.03) | na | 0.88 (0.63–1.23) | 1.57 (1.31–1.89) | |
No. of studies; I^{2}, %; P value^{b} | 18; 0; .45 | 4; 64; .04 | 1 | na | 3; 60; .08 | na | 6; 46; .10 | 7; 0; .83 | |
OR (95% CI)^{c} | 0.97 (0.82–1.13) | 0.96 (0.71–1.29) | 1.19 (0.71–2.04) | 0.94 (0.63–1.43) | 1.50 (1.06–2.11) | 1.60 (1.03–2.54) | 0.83 (0.66–1.04) | 1.69 (1.40–2.04) | |
SNRI | |||||||||
OR (95% CI)^{a} | 1.20 (0.53–2.72) | 1.09 (0.79–1.49) | na | na | na | na | na | 1.94 (0.96–3.93) | |
No. of studies; I^{2}, %; P value^{b} | 2; 55; .14 | 4; 64; .04 | na | na | na | na | na | 1 | |
OR (95% CI)^{c} | 1.00 (0.72–1.41) | 1.03 (0.77–1.42) | 1.23 (0.67–2.28) | 0.97 (0.60–1.63) | 1.55 (1.02–2.45) | 1.65 (0.98–2,80) | 0.86 (0.59–1.24) | 1.75 (1.24–2.47) | |
NRI | |||||||||
OR (95% CI)^{a} | na | 0.84 (0.61–1.18) | na | na | na | na | na | na | |
No. of studies; I^{2}, %; P value^{b} | na | 1 | na | na | na | na | na | na | |
OR (95% CI)^{c} | 0.60 (0.41–0.91) | 0.63 (0.41–0.87) | 0.61 (0.36–1.02) | 0.79 (0.41–1.57) | 0.94 (0.58–1.54) | 1.34 (0.66–2.70) | 0.52 (0.32–0.84) | 1.42 (0.81–2.49) | |
Low-dose SARI | |||||||||
OR (95% CI)^{a} | 0.70 (0.29–1.67) | na | na | na | 2.11 (1.37–3.25) | na | na | na | |
No. of studies; I^{2}, %; P value^{b} | 2; 79; .03 | na | na | na | 4; 0; .56 | na | na | na | |
OR (95% CI)^{c} | 1.03 (0.68–1.55) | 1.06 (0.70–1.58) | 1.03 (0.61–1.67) | 1.26 (0.63–2.47) | 1.60 (1.07–2.42) | 1.70 (0.96–2.89) | 0.89 (0.58–1.38) | 1.80 (1.17–2.76) | |
NaSSA | |||||||||
OR (95% CI)^{a} | 0.26 (0.11–0.60) | 0.95 (0.49–1.85) | na | na | 0.47 (0.31–0.73) | 1.07 (0.49–2.34) | na | 1.34 (0.85–2.10) | |
No. of studies; I^{2}, %; P value^{b} | 1 | 3; 60; .08 | na | na | 4; 0; .56 | 1 | na | 2; 0; .98 | |
OR (95% CI)^{c} | 0.64 (0.46–0.93) | 0.67 (0.47–0.95) | 0.64 (0.41–0.98) | 0.79 (0.42–1.45) | 0.63 (0.41–0.93) | 1.06 (0.65–1.72) | 0.55 (0.37–0.82) | 1.13 (0.78–1.62) | |
rMAO-A | |||||||||
OR (95% CI)^{a} | 0.61 (0.43–0.86) | na | na | na | na | 0.93 (0.43–2.03) | na | na | |
No. of studies; I^{2}, %; P value^{b} | 3; 0; .79 | na | na | na | na | 1 | na | na | |
OR (95% CI)^{c} | 0.61 (0.41–0.91) | 0.63 (0.41–0.97) | 0.61 (0.36–1.02) | 0.74 (0.37–1.52) | 0.59 (0.35–1.04) | 0.94 (0.58–1.54) | 0.52 (0.32–0.84) | 1.06 (0.67–1.66) | |
Hypericum | |||||||||
OR (95% CI)^{a} | 1.15 (0.71–1.85) | 1.14 (0.81–1.59) | na | na | na | na | na | 2.02 (1.41–2.88) | |
No. of studies; I^{2}, %; P value^{b} | 2; 24; .25 | 6; 43; .12 | na | na | na | na | na | 9; 43; .08 | |
OR (95% CI)^{c} | 1.16 (0.81–1.50) | 1.20 (0.96–1.51) | 1.16 (0.80–1.68) | 1.43 (0.81–2.64) | 1.13 (0.72–1.73) | 1.80 (1.21. 2.67) | 1.92 (1.20–3.16) | 2.03 (1.63–2.53) |
CI = confidence interval; CI = credible interval; hypericum = extract from Hypericum perforatum L.; rMAO-A = reversible inhibitor of monoaminoxidase A (moclobemide, minaprine); na = not available; NaSSA = noradrenergic and specific serotonergic antidepressive agent (mianserin, mirtazapine); NRI = noradrenaline reuptake inhibitor (reboxetine); OR = odds ratio; SARI = serotonin (5-HT_{2}) antagonist and reuptake inhibitor (trazodone); SNRI = serotonin-noradrenaline reuptake inhibitor (venlafaxine); SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic and tetracyclic antidepressant.
Note: Odds ratios >1 indicate more study discontinuation in patients receiving the treatment given in the row heading.
↵a Conventional meta-analysis of within-study comparisons with pooled odds ratios.
↵b Studies with direct comparisons available, with I^{2} value and P value from the χ^{2} test for heterogeneity.
↵c From network meta-analysis.